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Abstract: Exenatide is an incretin mimetic that is recently available in the US for the treatment 
of diabetes. There is a paucity of information on the effects of exenatide in glucocorticoid 
(GC)-induced diabetes. Although the effect of continuous intravenous infusion of exenatide on 
GC-induced glucose intolerance has been investigated before in healthy human males receiv-
ing oral prednisolone, we investigated the efficacy of a single subcutaneous dose of exenatide 
(3 µg/kg) in lowering blood glucose in GC-induced glucose intolerance in C57BL/6 mice. In a 
longitudinal experiment, the area under the curve (AUC) of oral glucose tolerance tests (OGTT) 
significantly increased after dexamethasone (P = 0.004), which was subsequently decreased by 
exenatide (P , 0.001). A cross-sectional experiment showed that exenatide improved glucose 
tolerance compared with placebo in a mouse model of dexamethasone-induced glucose intoler-
ance. AUC of OGTT in the exenatide group were significantly (P , 0.001) lower than in the 
placebo group. Insulin tolerance tests (ITT) demonstrated that exenatide decreased the ability 
of the mice to tolerate insulin compared with placebo. The AUC of ITT in the exenatide group 
were also significantly (P = 0.006) lower than in the placebo group. In conclusion, a single dose 
of exenatide was able to decrease glucose intolerance and insulin resistance in these placebo-
controlled experiments. Future clinical trials are justified to investigate the role of exenatide in 
the treatment of GC-induced glucose intolerance/diabetes.
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Glucocorticoids (GC) induce hyperglycemia,1 and hyperglycemia have an adverse effect 
on the outcome of chemotherapy for acute lymphocytic leukemia (ALL).2 Patients with 
hyperglycemia ($200 mg/dL) during induction chemotherapy with the hyper-CVAD 
regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone 
alternating with high-dose methotrexate and cytarabine) were found to have shorter 
complete remission durations than those with normal glucose.2 The patients had 
hyper-CVAD, which included dexamethasone 40 mg on days 1–4 and days 11–14 in 
  odd-number courses (courses 1, 3, 5, and 7) and methylprednisolone 50 mg twice daily 
on days 1–3 in even-number courses (courses 2, 4, 6, and 8). Antidiabetic medications 
such as thiazolidinediones (eg, pioglitazone)3,4 and biguanides (metformin)3 can be used 
to improve the insulin resistance induced by GC. Insulin has been commonly used to 
manage acute exacerbation in hyperglycemia induced by glucocorticoids in most clini-
cal settings.5 However, insulin has a promoting effect on growth and chemoresistance 
to daunorubicin of leukemic cell lines and primary samples of ALL (Yeung, unpub-
lished data); therefore, a rapidly effective therapy without a malignancy-promoting 
effect needs to be identified for the treatment of GC-induced hyperglycemia in ALL Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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patients   undergoing chemotherapy before medications such 
as metformin and pioglitazone can exert their full antidiabetic 
effect or when oral antidiabetic medications are unable to 
control hyperglycemia satisfactorily. Exenatide is a glucagon-
like peptide-1 mimetic recently approved for the treatment 
of diabetes. Our recent investigation did not find any direct 
promoting effect of exenatide on cancer cells.6 Its effective-
ness for GC-induced hyperglycemia is unknown. There-
fore, we tested the effectiveness of exenatide in controlling 
GC-induced hyperglycemia in a mouse model.
We induced glucose intolerance by intraperitoneal 
(IP) injection of dexamethasone (dexamethasone sodium 
phosphate for injection, APP Pharmaceuticals, Raleigh, 
NC, USA; 4 mg/mL) into adult C57BL6 mice (males and 
females). Blood glucose levels were measured using a Free-
Style Glucose Meter (Abbott Laboratories, Abbott Park, 
IL, USA). Blood samples were collected by cutting into the 
soft tissue of the distal 2-mm portion of the mice’s sterilized 
tails using a scalpel and gentle squeezing to obtain two or 
more drops of blood. The first drop was discarded; the second 
drop was applied on the test strip. Additional blood (up to 
60 µL) was collected by submandibular bleeding (superficial 
temporal vein) for hormone analysis when indicated. An oral 
glucose tolerance test (OGTT) was performed after a 15- to 
18-hour fast. Blood glucose levels were measured immedi-
ately prior to glucose administration (0 min) and at 15, 30, 
60, and 120 min after glucose (1.5 g/kg as a 50% w/v solution 
in water) administration by orogastric gavage. An insulin 
tolerance test (ITT) was performed after a 6-hour fast. Blood 
glucose levels were measured immediately prior to insulin 
administration (0 min) and at 15, 30, 60, and 120 min after 
recombinant human insulin (0.75 IU/kg) IP administration.
Area under the curve (AUC) for OGTT and ITT from 
each animal were calculated by interpolation and integration. 
Changes in AUC or in hormone levels, where appropriate, 
were compared. For comparisons between the two groups, 
Student’s t-test or Mann–Whitney rank-sum test were used, 
where appropriate, based on the normality of distribution 
and equality of variances.
Using the mouse model of diabetes induced by 
dexamethasone (20 mg/kg/day IP every morning for 
5 days), a longitudinal experiment was performed. OGTT 
were performed in nine 8- to 10-week-old C57BL/6 mice at 
baseline and after dexamethasone injection on day 4. After 
dexamethasone injection on day 5, the mice were injected with 
exenatide (Lilly, Indianapolis, IN, USA; 250 µg/mL, diluted 
in sterile normal saline to appropriate volume just before use) 
3 µg/kg subcutaneously (SQ) 1 hour prior to the OGTT. The 
average blood glucose levels during the OGTT increased 
at most of the time points from baseline to day 4 after 
dexamethasone administration, and decreased at most of 
the time points from baseline and day 4 to day 5 after dexa-
methasone and exenatide administration (Figure 1A). The 
average change in AUC between the first and second OGTT of 
each mouse was significantly higher than 0 (one sample t-test, 
P = 0.004); the average change in AUC between the second 
400
300
200
100
0
0 100 100 100 0 0
Time (min)
B
l
o
o
d
 
g
l
u
c
o
s
e
 
(
m
g
/
d
L
)
Baseline  Day 4  Day 5 
Dexamethasone
+ Exenatide
Dexamethasone x 4 days
•
•
• •
•
• • •
•
•
•
•
•
• •
15000
10000
5000
−5000
−10000
−15000
−20000
−25000
Between baseline and after
4 days of dexamethasone
Between after 4 days of dexamethasone
and after 5 days of dexamethasone plus
one dose of exenatide
Between baseline and after
2 days of  methylprednisolone
Between after 2 days of methylprednisolone
and after 3 days of methylprednisolone plus
one dose of exenatide 
0
Longitudinal
studies
C
h
a
n
g
e
 
i
n
 
O
G
T
T
 
A
U
C
(
m
i
n
·
m
g
/
d
L
)
A
B
Figure 1 exenatide suppressed the rise in blood glucose after an oral glucose load 
in mice with glucocorticoid-induced glucose intolerance. A) Average blood glucose 
levels of nine adult C57BL/6 mice during an OGTT performed on three occasions are 
plotted against time. The error bars represent 95% CI. After baseline OGTT, each 
mouse was injected dexamethasone (20 mg/kg/day) IP for 4 days. The day 4 OGTT 
was performed several hours after dexamethasone injection in the morning. On 
day 5, the OGTT was performed after injection of dexamethasone IP and exenatide 
(3 µg/kg) SQ. B) The average change in AUC between the first and second OGTT of 
each mouse and between the second and third OGTT are plotted in the left panel for 
the longitudinal experiment described in A. Similar data for a separate experiment 
using a less potent glucocorticoid (methylprednisolone) and shorter duration than in 
A) are plotted in the right panel. The error bars represent 95% CI.
Abbreviations: AUC, area under the curve; CI, confidence intervals; IP, intraperitoneal; 
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and third OGTT was significantly lower than 0 (one sample 
t-test, P , 0.001) (Figure 1B). Therefore, dexa  methasone, 
given in the manner described, increased glucose intolerance 
in C57BL/6 mice, and a single SQ injection of exenatide 
(3 µg/kg) significantly suppressed the rise in blood glucose 
after the oral glucose load.
In a second longitudinal experiment, ten 8- to 10-week-
old C57BL/6 mice were injected with methylprednisolone 
(methylprednisolone sodium succinate for injection, Pfizer, 
New York, NY, USA; 40 mg/mL diluted to 4 mg/mL in normal 
saline) 20 mg/kg/day IP every morning for 3 days instead of 
dexamethasone. The lower potency of methylprednisolone 
and shorter duration of glucocorticoid treatment than in the 
first experiment was intended to test whether exenatide would 
induce hypoglycemia when GC-induced glucose intolerance 
was mild. OGTT were performed at baseline, day 2, and 
day 3, with the exenatide given 1 hour prior to the OGTT 
on day 3. The average change in AUC between the first and 
second OGTT of each mouse was not significantly higher than 
0 (one sample t-test, P = 0.476); the average change in AUC 
between the second and third OGTT was significantly lower 
than 0 (one sample t-test, P = 0.001) (Figure 1B). Although 
a single dose of exenatide significantly reduced the AUC in 
the methylprednisolone-treated mice, the glucose levels were 
stable within the normal range for the duration of the OGTT, 
and no hypoglycemia (defined as blood glucose ,80 mg/dL) 
was observed.
To corroborate the effect of a single dose of exenatide on 
GC-induced glucose intolerance, a cross-sectional, placebo-
controlled experiment was performed using the mouse model of 
diabetes induced by dexamethasone (20 mg/kg/day for 5 days). 
Exenatide (3 µg/kg SQ 1 hour prior to OGTT) improved glucose 
tolerance (Figure 2A) compared with a placebo control group 
(Figure 2A). Using the same mouse model, an ITT demon-
strated that exenatide (Figure 2B) decreased the ability of the 
mice to tolerate insulin compared with placebo (Figure 2B). 
AUC of OGTT and ITT for the exenatide group and the con-
trol group are shown in Figure 2C. In the OGTT, the mean 
AUC of the exenatide-treated mice (n = 18) was significantly 
(P , 0.001, Mann–Whitney rank-sum test) lower than that of 
the placebo-treated mice (n = 17). In the ITT, the mean AUC 
of the exenatide-treated mice (n = 9) was also significantly 
(P = 0.006, Mann–Whitney rank-sum test) lower than that of 
the placebo-treated mice (n = 13). Therefore, a single dose of 
exenatide was able to decrease glucose intolerance and insulin 
resistance in these placebo-controlled experiments.
Extra blood samples were collected at time 0   (baseline) 
and 30 min after glucose administration during the OGTT in a 
subset of animals (n = 5 each for exenatide and control groups) 
for hormone analyses. A total volume of 20 µL of plasma from 
each time point was assayed in duplicate in a multiplex immu-
nodetection analysis for amylin, C-peptide, ghrelin, gastric 
inhibitory polypeptide, glucagon-like peptide-1, interleukin-6, 
insulin, glucagon, resistin, leptin, monocyte chemotactic 
protein-1, pancreatic polypeptide, polypeptide YY, and tissue 
necrosis factor-α (Milliplex Mouse Metabolic Hormone Mag-
netic Bead Panel, Millipore, Billerica, MA, USA). Amylin, 
tissue necrosis factor-α, monocyte chemotactic protein-1, 
pancreatic polypeptide, polypeptide YY, glucagon, glucagon-
like peptide-1, and ghrelin were below the detection limits. 
Gastric inhibitory polypeptide, interleukin-6, and resistin did 
not show any consistent changes between baseline (time 0) and 
30 min after oral glucose load. The changes between the two 
time points (∆Hormone0–30 min) in C-peptide, insulin, and leptin 
are plotted for the exenatide-treated group and the placebo-
treated control group in Figure 2D. Although there might be 
trends that exenatide decreased the change in C-peptide and 
insulin levels and that exenatide increased the rise in leptin 
level 30 min after the orogastric glucose load, the variances in 
the data were too large to reach any statistical conclusions.
Exenatide is highly unlikely to have a promoting effect 
on the growth of malignancies. Despite concerns based on 
the observation of benign c-cell thyroid adenomas in rats 
that received exenatide for 2 years, there is no evidence to 
support a link between exenatide and medullary thyroid 
cancer. Our published data show that exenatide does not have 
any promoting effects on the growth of breast cancer and 
pancreatic cancer cell lines in cell culture.6 Although exenatide 
enhances glucose-dependent insulin secretion in type 2 diabetic 
patients by activation of glucagon-like peptide-1 receptor, 
exenatide delays gastric emptying and reduces postprandial 
glucose absorption and peak plasma insulin level.7 There is 
cell culture experimental evidence to suggest that GC induce 
apoptosis in insulin-secreting cells and that exenatide can 
protect against the GC-induced apoptosis.8 The incretin effect 
is impaired after induction of reduced glucose tolerance 
and insulin resistance in healthy males by oral prednisolone 
treatment, a high-calorie diet, and physical inactivity.9 At the 
2010 meeting of the American Diabetes Association, van Raalte 
et al reported that exenatide prevented glucose intolerance as 
assessed during a standardized meal test.10 Our mouse model 
data have also shown that exenatide is effective in reversing 
GC-induced glucose intolerance. As shown by hyperglycemic 
clamping, exenatide improves β-cell function in humans treated 
with prednisolone.10 Our ITT data suggest that exenatide may 
also be acting on the peripheral tissues and improving their Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011:4 submit your manuscript | www.dovepress.com
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sensitivity to insulin. The trend in the hormone data associated 
with the OGTT in our study suggests that increasing insulin 
secretion may not be the primary mechanism for the efficacy of 
exenatide in lowering postprandial glucose. We speculate that 
delay in gastric emptying, resulting in delayed or decreased 
absorption of glucose, may also play a major role. Further study, 
including parenteral glucose tolerance tests, long-term obser-
vations, and/or evaluation of peripheral sensitivity to insulin 
by glucose clamping, may further elucidate the mechanisms 
involved in the beneficial effect of exenatide in GC-induced 
glucose intolerance.
Because human data10 and our mouse data have shown 
that exenatide is effective in reversing GC-induced glucose 
intolerance, exenatide may be a more appropriate agent 
than exogenous insulin or insulin secretagogues in the 
management of acute exacerbations of hyperglycemia in 
cancer patients, especially in the clinical scenario of GC-
induced hyperglycemia encountered in the treatment of 
ALL patients. Clinical trials are justified to evaluate the 
effectiveness of exenatide for glucose control in GC-induced 
glucose intolerance and whether exenatide can reverse the 
decrease in complete remission duration and survival in ALL 
patients with steroid-induced hyperglycemia.
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Figure 2 exenatide suppressed the rise in blood glucose after an oral glucose load and decreased insulin tolerance in dexamethasone-treated mice compared with placebo. 
A) Using the mouse model of diabetes induced by dexamethasone (20 mg/kg/day for 5 days), the cross-sectional comparison of OGTT between an exenatide-treated group 
(squares) and a placebo-treated control group (circles) is shown. error bars – 95% CI. B) Using the same mouse model, the cross-sectional comparison of ITT between an 
exenatide-treated group (squares) and a placebo-treated control group (circles) is shown. error bars – 95% CI. C) AUC for OGTT in A and ITT in B were plotted for the 
exenatide and control groups as labeled. error bars – 95% CI. D) extra blood samples were collected at time 0 (baseline) and 30 min after glucose administration during 
OGTT in a subset of animals for hormone analyses. The changes in C-peptide, insulin, and leptin between the two time points were plotted for the exenatide-treated group 
(dark bars) and the placebo-treated control group (white bars). error bars – standard errors.
Abbreviations: AUC, area under the curve; CI, confidence intervals; IP, intraperitoneal; ITT, insulin tolerance test; OGTT, oral glucose tolerance test.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
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